The falsehoods being spread about biosimilars that don’t match up with reality.
The Power of PBMs and Biosimilars, 2025 Launches of the Stelara Biosimilars, the IRA and Interchangeability | Q&A with Craig Burton, MBA
The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and lobbying group for the biosimilars industry.
Read More
Health of the Biosimilars Industry, Getting Rid of Clinical Trials, PBMs As Obstacles and Other Biosimilar Topics | Q&A With Craig Burton, MBA
We spoke recently with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and lobbying group for the biosimilars industry.
FDA Approves Third Biosimilar of Actemra
The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.
Wezlana, First Stelara Biosimilar To Hit the Market, Available Only Through Optum's Nuvaila
Using a single PBM as the sole distribution channel is unprecedented.
In This the Year for a Star Turn by Stelara Biosimilars?
Will the Stelara biosimilars be a reprise of the Humira biosimilars in 2023 and be slow to catch on?
Two Prolia Biosimilars, One for Xolair Are in the Offing, Says AscellaHealth Report
The report also discusses the spurt of Stelera biosimilar approvals in late 2024.
